Kornimate/medical-research-clean huggingface dataset:
early interim 18f-fdg-pet and 18f-flt-pet for predicting treatment response and survival in metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: we aim to investigate the value of 3'-deoxy-3'-18f-fluorothymidine (18f-flt) and 18f-fluorodeoxyglucose (18f-fdg) positron emission tomography/computed tomography (pet/ct) for early prediction of treatment response and survival in patients with metastatic breast cancer after salvage therapy.

patients with metastatic breast cancer were enrolled and received pet/ct using 18f-flt and 18f-fdg at baseline, after 1st cycle , and after 2nd cycle of systemic chemotherapy. the standard reference for treatment response was classified according to response evaluation criteria in solid tumors (recist) 1.1 criteria for contrast-enhanced ct (ce-ct) after 3 months of systemic chemotherapy. the metabolic response on pet was assessed according to pet response criteria in solid tumors (percist) criteria and was correlated to the treatment response, progression-free survival (pfs), and overall survival (os).

Eligibility criteria:
inclusion criteria: * participants must have histological evidence of breast cancer of any stage * participants must be diagnosed with metastatic breast cancer * participants should be willing and able to have both pet-ct scans * participants should be eligible for and plan to undergo systemic chemotherapy and should be seen by a oncologist prior to beginning the study * participants should have the ability to understand and the willingness to sign a written informed consent document * participants must sign a study specific consent form prior to registration exclusion criteria: * patients have been diagnosed with other malignancy * patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or significant inflammation at treatment site or psychiatric illness/social situations that would limit compliance with study requirements or whose lab values do not meet the criteria above are excluded * pregnant women are excluded from this study * breast feeding women are excluded from this study

Keywords: 18f-fluorothymidine 18f-fluorodeoxyglucose metastatic breast cancer
a test of different degrees of cost sharing on program uptake and attendance

Conditions: Obesity

Summary: to test the uptake of four different cost sharing discounts for enrolling in the weight watchers weight loss program as well as outcomes (program attendance and weight loss) over 12 months.


Eligibility criteria:
inclusion criteria: 1. must be employee of vanguard health systems over the age of 18 2. must have a bmi of 21 or greater exclusion criteria: 1. must not be under the age of 18 2. must not have a bmi lower than 21

Keywords: obesity weight loss program incentives
a study of substitution of 5-fu (fluorouracil) by capecitabine in scheme of chemo-radiotherapy in patients with squamous cell carcinoma of the anal canal.

Conditions: Anal Canal Cancer.

Summary: the squamous cell carcinoma (scc) of the anal canal is an uncommon neoplasia which corresponds to 1-5% of intestinal tumors. however the risk of scc of the anal canal has been growing recently. the standard treatment of anal cancer stage ii-iii is multimodal and consists of combined chemotherapy (infusional 5-fluorouracil and mitomycin) and radiotherapy. this scheme currently used was proposed in 1974, and since then no other effective treatment has been developed. the purpose of this study is to determine the efficacy and toxicity of the combination of capecitabine and mitomycin with radiotherapy in patients with carcinoma of the anal canal. for this will be selected 51 patients to be treated with chemo-radiotherapy. the primary endpoint will be local control rate after 6 months of the end of radiotherapy and chemotherapy, defined by the rate of radiological and clinical neoplasia.


Eligibility criteria:
inclusion criteria: * invasive anal canal scc histologically confirmed, t2-4 n0 m0, t (anyone) n1-3 m0 - according to tnm staging system. * age ≥ 18 years. * eastern cooperative oncology group (ecog) performance status 0 - 2. * adequate medullar function, defined as: absolute neutrophil count ≥ 1,5×109/l; platelets ≥100×109/l; hemoglobin ≥10g/dl. * serum ast (aspartato aminotransferase) and alt (alanine aminotransferase) \< 3 × uln (upper limit of normal). * serum creatinine ≤ 1,5 uln and clearance of creatinine estimated (cockcroft- gault) ≥ 50 ml/min. * signed written informed consent. exclusion criteria: * major surgical procedure within 4 weeks of the beginning of the treatment. * history of severe systemic or psychiatric disease. * previous treatment for anal canal carcinoma or other cancer. * for female patients, current pregnancy and/or lactation * unstable angina or acute myocardial infarction within 6 months. * concomitant use of oral anticoagulants * hiv positive with result of cd4 ≤ 200. * previously pelvic radiotherapy.

Keywords: anal canal cancer;capecitabine; mitomycin; radiotherapy.
ultrasound guidance versus electrical stimulation for perineural catheter insertion

Conditions: Postoperative Pain

Summary: this research study is to determine the relative times for perineural catheter placement with the use of ultrasound versus electrical stimulation. the perineural catheter is placed next to the nerves through which local anesthetic is placed to provide pain control following surgery. this study may determine if one method is associated with increased success rate and patient comfort.

primary specific aim: to determine if the relative times for perineural catheter placement with the use of ultrasound versus electrical stimulation. hypothesis: compared with the use of electrical stimulation, the use of ultrasound guidance when inserting a perineural catheter is associated with a decreased time of placement. secondary specific aim: to determine if other possible benefits of perineural catheter placement associated with the use of ultrasound guidance versus electrical stimulation. hypothesis: compared with the use of electrical stimulation, the use of ultrasound guidance when inserting a perineural catheter is associated with an increased surgical block success rate and catheter-placement success rate, as well as decreased patient discomfort and incidence of venous puncture.

Eligibility criteria:
inclusion criteria: * undergoing surgery with a planned perineural catheter for postoperative analgesia * catheter in the interscalene, infraclavicular, popliteal, or femoral anatomic location * age 18 years or older exclusion criteria: * pregnancy * inability to communicate with the investigators and hospital staff * incarceration

Keywords: catheter ultrasound guidance nerve stimulation electrical stimulation nerve block ucsd timed placement surgery catheter placement time
a research study to bank samples for future evaluation to identify biomarkers that predispose crohn's disease and ulcerative colitis patients to develop hepatosplenic t-cell lymphoma (hstcl)

Conditions: Hepatosplenic T-Cell Lymphoma

Summary: this study is designed to collect tissue samples from the biopsy specimen that was used to diagnose hepatosplenic t-cell lymphoma (hstcl), additional patient information, and if possible, to obtain additional samples including a single blood sample, a buccal swab sample and/or a bowel tissue sample. samples obtained will be stored by the sponsor for future testing. in addition, demographic and clinical patient information will be collected. the study will be conducted in north america. patients eligible for enrollment include males or females with ibd of any age who have a confirmed diagnosis of hstcl. patients will be identified through the sponsor's adverse event reporting systems. cases reported to the sponsor's medical information center will be queried to ascertain if the reporter is interested in participating in the study. where appropriate, cases may also be identified through the sponsor's new or on-going clinical trials and registries. samples may be collected from living patients or from stored tissue of deceased patients. this study will not restrict or introduce any therapeutic interventions, including medications. all patients will continue to be managed by their personal physicians. no healthy subjects will be enrolled in this study.


Eligibility criteria:
inclusion criteria: * patients with inflammatory bowel disease with a confirmed diagnosis of hepatosplenic t-cell lymphoma * provide written informed consent (either by the patient or his/her legal representative). consent from a legally acceptable representative of a deceased patient will be obtained for enrollment into the study and sample collection * be willing to provide a tumor biopsy sample for the study exclusion criteria: * has any condition that, in the opinion of the investigator, would make participation not be in the best interest (for example, compromise the well-being) of the patient or that could prevent, limit, or confound the protocol-specified assessments * is unable to provide critical clinical and/or demographic patient and/or sample information

Keywords: lymphoma, t-cell, peripheral, infliximab, golimumab, remicade, simponi, ulcerative colitis, crohn's disease, inflammatory bowel disease
non-invasive screening of fetal trisomy 21 by digital pcr

Conditions: Trisomy 21

Summary: in france, as in many countries of the world, trisomy 21 or down syndrome (ds) is the subject of an antenatal screening based on a risk calculation (r) including the assay of biochemical markers in the maternal blood, and the measurement of a fetal ultrasound parameter (nuchal translucency). in the population of pregnant women said to be at high risk (r\> 1/250), confirmation of the diagnosis of ds is made by invasive sampling (trophoblast biopsy or amniocentesis), which allows the establishment of fetal karyotype. in addition to limited sensitivity (80 to 85% depending on the techniques), this screening is an anxiety factor (8% false positives), and miscarriages of euploid fetuses (normal karyotype) in 1% of cases (procedures invasive). the plasma of a pregnant woman contains a mixture of free dna of maternal (90%) and fetal origin (cffdna for cell free fetal dna) (about 10%, but this proportion increases in cases of fetal trisomy 21. the proportion of cffdna is sufficient to qualitatively and quantitatively study specific genetic markers of a pair of chromosomes. it is therefore possible to evaluate the quantity of markers chromosome of interest relative to a reference chromosome marker, and to calculate a marker / marker ratio of interest, theoretically identical for all autosomes (chromosomes 1 to 22) during euploid pregnancy. in case of fetal aneuploidy (for example, trisomy 21), this ratio is unbalanced for the chromosomal pair involved. advances in technology, such as high-throughput mass sequencing (mps) and digital pcr (dpcr), now make it possible to consider the diagnosis of fetal maternal ds through the study of cffdna. several teams have already published on this subject with the mps technique, applied directly to free dna from maternal plasma, or after a cffdna isolation step. this involves sequencing the dna fragments present in the sample and placing them back on their original chromosome. in case of trisomy 21 fetal, one seeks to put in evidence of an excess of sequences from chromosome 21. these techniques require expensive equipment (sequencer, bioinformatic platform, servers) and a technical time and important analysis (often several days for a single run). concerning the research of aneuploidies by digital pcr (dpcr), few publications are today due to the absence of sufficiently powerful instruments until recently. dpcr is less expensive.


Eligibility criteria:
inclusion criteria: * women with high risk of fetal trisomy 21 with maternal screening test, who benefited of invasive sampling exclusion criteria: * women with twin pregnancies * pregnancies with other chromosomal abnormalities

Keywords: nipt digital pcr trisomy 21 prenatal diagnosis
perform necrotic cavity lavage or not after debridement of infected pancreatic necrosis

Conditions: Pancreatitis,Acute Necrotizing; Pancreas Necrosis

Summary: the infected pancreatic necrosis (ipn) should be treated by debridement and drainage. in recent years, the results of clinical research show that minimally invasive debridement such as video-assisted (laparoscope, nephroscope, endoscopy, etc.) and total laparoscopic debridement can significantly improve the prognosis of ipn patients. after a long period of clinical practice, laparoscope-assisted debridement was selected as the main surgical method in our center. in many large-scale clinical studies, patients after surgery underwent necrotic cavity lavage (such as small omental sac lavage, retroperitoneal space lavage, peripancreatic lavage, etc.), but its necessity and clinical significance were not clearly stated in the guidelines. at present, the clinical research mainly focuses on the improvement of minimally invasive debridement, and less on the necessity of lavage. in the past, necrotic cavity lavage was performed in ipn patients, but long-term clinical observation showed that lavage may lead to spread of infection and increase the incidence of lower extremity venous thrombosis which is not accorded with eras(enhanced recovery after surgery). therefore, since 2012, our center has stopped necrotic cavity lavage for ipn patients after debridement. we retrospectively analyzed the therapeutic effect from february 2014 to august 2017 and found that even without necrotic cavity lavage, better therapeutic effect could be achieved. meanwhile it can simplify the operation process and avoid infection spread. this treatment method provides a new idea. however, it is a retrospective study not a randomized controlled trials(rct) which is low effectiveness of proof. therefore, we design this rct to verify the necessity of necrotic cavity lavage after laparoscope-assisted debridement for patients with infected pancreatic necrosis.


Eligibility criteria:
inclusion criteria: 1. diagnosis of ipn 2. onset time of \>4 weeks 3. performance of lad for ipn 4. provision of written informed consent exclusion criteria: 1. the highest temperature in 24 hours of ≥38.5ºc 2. new organ failure occurring within 24 hours after the operation 3. digestive tract fistula, biliary tract or digestive tract obstruction, or bleeding occurring within 24 hours after the operation 4. abdominal pressure of ≥10 mmhg within 24 hours after the operation 5. traumatic pancreatitis or a pancreatic fistula-related infection after the pancreatic operation

Keywords: acute pancreatitis infected pancreatic necrosis laparoscope-assisted debridement necrotic cavity lavage
ku alternate meal energy level study

Conditions: Obesity; Weight Loss

Summary: compare intermittent versus continuous calorie restriction to learn more about these eating plans and determine whether they are useful and effective to lose weight and keep it off.

the purpose of this study is to provide evidence for the feasibility of an alternative weight control strategy by comparing two diets to see how intermittent calorie restriction compares to continuous or daily calorie restriction for weight loss in 35 adults with overweight or obesity. these diets will be incorporated into a comprehensive and intensive weight management program involving weekly health education meetings, regular diet and physical activity tracking, and feedback from a registered dietitian. each intervention includes 3 months of weight loss and 3 months of weight maintenance. group 1: follow a low-calorie diet every day (1,200 - 1,500 calories daily) group 2: follow an intermittent very-low calorie diet (500-800 calories). participants in this group will alternate between days of 500-800 calories and days of structured eating using healthy eating principles.

Eligibility criteria:
inclusion criteria: 1. age 21-65 years. 2. bmi 25-35. patients with a bmi less than 25 are not classified as overweight and individuals with a bmi \>35 may require more aggressive weight management strategies. 3. clearance for participation from their pcp. exclusion criteria: 1. participation in a research project or formal program involving weight loss or exercise in the previous 6 mos., as these proximal experiences may impact the results of this study. 2. participation in a regular exercise program (i.e., \> 500 kcal/wk. of planned activity as estimated by questionnaire \[34\]. 3. not weight stable (-/+ 5%) for 6 mos. prior to intake. this will be determined by phone screen and self-report on the health history questionnaire 4. unwilling to be randomized to one of two diet strategies for weight loss. 5. pregnant during the previous 6 mos., lactating, or planned pregnancy in the following 6 mos. 6. serious medical risk (e.g. diabetes, cancer, cardiovascular disease) as determined by the individual's physician via the clearance to participate in the investigation. 7. disordered eating as determined by the eating attitudes test using a score of 20 or greater \[35\]. this score indicates the need for counseling outside the scope of this study. 8. current treatment for psychological problems, or taking psychotropic medications. addressing psychological problems is outside the scope of this study. 9. medications known to significantly influence weight. 10. adherence to specialized diet regimens (e.g., multiple food allergies, vegan, etc.) 11. do not have access to or independence over grocery shopping and meal preparation (i.e. those in military, college with cafeteria plan, etc.). 12. if participants have recently undergone ct (computed tomography), pet, fluoroscopic, or nuclear medicine studies within the past year.

Keywords: weight management obesity very-low calorie diet intermittent diet
effects of bioflavanoids on vascular wall remodeling in patients with varicose veins

Conditions: Varicose Veins of Lower Limb; Varix; Vascular Diseases; Leg Edema

Summary: the study is aimed at assessing the dynamics of changes in biochemical markers of venous wall remodeling (type 1 plasminogen activation inhibitor (pai-1), fibronectin (fibronectin, fn), vimentin (vimentin, vm), von willebrand factor (vwf), pecam-1 (cd31) ) in patients with c2s-c3s varicose veins compared with healthy volunteers while taking venarus® (diosmin in combination with hesperidin).

the study will include 80 patients with varicose veins of the lower extremities, ceap (ceap classification stands for clinical (c), etiological (e), anatomical (a), and pathophysiological (p)) clinical class c2s-c3s and 20 healthy volunteers of similar age, gender, and ethnicity (100 patients altogether). the study participants will be divided into five groups: group a: 20 patients with varicose veins who will be treated conservatively - receive the drug "venarus®" (diosmin in combination with hesperidin) at a dosage of 1000 mg once daily for 6 months; group b: 20 patients with varicose veins c2s-c3s who are not prescribed conservative therapy with venoactive drugs and will not undergo invasive treatment; group c: 20 patients with varicose veins who will undergo invasive treatment (endovenous laser ablation with miniphlebectomy), followed by venarus at a dosage of 1000 mg once daily for 6 months; group d: 20 patients with varicose veins who will undergo invasive treatment (endovenous laser ablation with miniphlebectomy), after which no venoactive drugs will be prescribed. group e: 20 healthy volunteers without clinical and ultrasound signs of varicose veins. all subjects in groups a, b, c, and d will receive elastic compression.

Eligibility criteria:
inclusion criteria: * the study will include men or women over 18 years of age with varicose disease of the lower extremities c2-c3 according to the ceap classification, confirmed by ultrasound duplex scanning of the veins of the lower extremities exclusion criteria: * the presence of neoplasms, previous operations on the vessels of the lower extremities, deep vein thrombosis, severe concomitant diseases, including infectious ones, pregnancy, lactation

Keywords: bioflavonoids venous remodeling varicose veins
single-port versus multi-port laparoscopic surgery for ectopic pregnancy

Conditions: Ectopic Pregnancy

Summary: this study aims to compare the effectiveness and safety of single-port versus multi-port laparoscopic surgery in the treatment of ectopic pregnancy

single-port laparoscopic surgery has become one of the treatment options for ectopic pregnancy with certain advantages such as reduced numbers of incision and scars, and increased patient's satisfaction post-surgery. at hung vuong hospital, the investigators do not have data about the application potential of single-port laparoscopic surgery for ectopic pregnancy treatment. therefore, the investigators carry out this project to compare the effectiveness and safety of single-port versus traditional multi-port laparoscopic surgery in the treatment of ectopic pregnancy.

Eligibility criteria:
inclusion criteria: * 18 years old or older pregnant women who are indicated for laparoscopic surgery in the treatment of ectopic pregnancy. * agree to participate and give a consent exclusion criteria: * allergic reactions to anesthetics * hemodynamic instability * ruptured ectopic pregnancy

Keywords: laparoscopic surgery single-port laparoscope multi-port laparoscope
research for the molecular imaging of the pd-l1 targeting tracer

Conditions: Solid Tumor; Lung Cancer

Summary: to use the molecular probe pet radionuclide (ga-68 or f-18) wl12 peptide to detect the expression of pd-l1 in the primary and metastatic lesions in patients with solid tumor; to detect the expression heterogeneity of pd-l1 in the lesion and inter-lesions; to observe the change of pd-l1 expression in the course of treatment. to provide an approach for screening patients with high expression of pd-l1, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the individualized antitumor treatment of targeted drugs.

in many clinical trials, anti-pd-1/pd-l1 mabs have achieved great success than expected in a variety of refractory and recurrent tumor patients. the latest research shows that it is not all cancer patients would respond to anti-pd-1/pd-l1 mabs. at present, immunohistochemistry (ihc) is still a common method to screen patients that will benefit from this therapy by detecting the expression level of pd-1 and pd-l1. however, the results of ihc were not very exact because of limitations of ihc such as the heterogeneity of expression, the influence of host cell pd-l1 expression and the changes in the course of the disease. moreover, the tumor tissue used in ihc must obtained through the invasive method. it is difficult to dynamically monitor the expression level of pd-1 / pd-l1 during the treatment. immuno-pet molecular imaging by radiolabeling anti-pd-1/pd-l1 mabs with radionuclides can be used to noninvasive assessment of biodistribution of monoclonal antibodies and provide a new strategy for patient screening. in this study, 18f-wl12 or 68ga-wl12 pet / ct imaging will be performed in patients with solid tumors to access the potential of 18f-wl12 or 68ga-wl12pet / ct to screen patients who can benefit from js001 treatment.

Eligibility criteria:
inclusion criteria: * 1. aged \>18 years old; ecog 0 or 1; * 2. patients with solid tumors; * 3. has at least one measurable target lesion according to response evaluation criteria in solid tumors (recist v1.1); * 4. life expectancy \>=12 weeks. exclusion criteria: * 1. significant hepatic or renal dysfunction; * 2. is pregnant or ready to pregnant; * 3. cannot keep their states for half an hour; * 4. refusal to join the clinical study; * 5. suffering from claustrophobia or other mental diseases; * 6. any other situation that researchers think it is not suitable to participate in the experiment.